BEIJING – Roughly half of the new medicines entering human trials may now begin in Chinese laboratories, according to the figures discussed in the video. Western drugmakers aren’t waiting years to develop every replacement themselves. They are paying Chinese biotech companies for promising compounds, early trial data, and a head start. That shift matters because […] The post How China Is Reshaping Big Pharma first appeared on Chiang Rai Times.